Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Immunotherapy could fill unmet need in leptomeningeal metastases
Key clinical point: Pembrolizumab has antitumor activity against leptomeningeal metastases of solid tumors.
Major finding: The CNS response rate was 38%, with two patients having complete responses lasting 9 months and more than 3 years, respectively.
Study details: A single-arm, open-label, phase 2 trial of pembrolizumab in 13 patients with leptomeningeal metastases from solid tumors.
Disclosures: The trial was funded by Merck, the National Institutes of Health, the Lung Cancer Foundation of America, the International Association for the Study of Lung Cancer, and Johns Hopkins University Seed Grants. Dr. Naidoo disclosed relationships with AstraZeneca, Merck, Bristol Myers Squibb, and Roche/Genentech.
Naidoo J et al. SITC 2020, Abstract 788.